Incyte Corporation

137.19 +3.63(2.72%) Date: Jul 26, 4:25PM EDT

Incyte Corporation

Incyte Corporation (INCY) Competitor MYSTIC IO/IO PFS Expected Imminently

PFS results are anticipated mid-2017 and final OS data in 2018. Notably, several interim analyses for OS are included in trial protocol, and it is unclear what information will be provided to the public

Gabelli Lists Incyte Corporation (INCY) as Top Pick, Sees Gilead Sciences, Inc. (GILD) as Possible Buyer

Incyte's stock valuation is likely to benefit from additional Epacadostat data and potential oncology takeout

Credit Suisse On Incyte Corporation (INCY)

In the ASCO presentation, the firm saw some PK/PD data that may have suggested GDC-0919 was less potent (or maybe it was under-dosed) than Bristol or Incyte's IDO

Incyte Corporation (INCY): Thoughts on Epacadostat In NSCLC

Incyte and Merck reported Keytruda (PD-1) plus epacadostat (IDO) combination data on Saturday from the cohort of non-small cell lung cancer (NSCLC) patients in the ECHO- 202 study

Incyte Corporation (INCY): NSCLC Primary Focus For Most Investors

Keytruda demonstrated a ORR of 17% in a 1L+ SCCHN trial. Opdivo + Yervoy (CheckMate-032) trial in 2L+ bladder cancer showed an ORR of 38.5% vs. 24.4% for Opdivo alone